UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that outpaced consensus estimates. Revenues climbed 8% year‑on‑year (YoY) to GBP 8.5 billion (USD 11.3 billion) in constant currency terms, underscoring the company’s resilient growth trajectory.
Specialty Medicines Portfolio Fuels Momentum
The Specialty Medicines segment led the charge, expanding 16% YoY to GBP 3.4 billion (USD 4.5 billion). Within this portfolio, oncology sales surged 39% to GBP 511 million (USD 680 million), respiratory, immunology & inflammation grew 15% to GBP 954 million (USD 1.27 billion), and HIV drug sales rose 12% to GBP 1.94 billion (USD 2.58 billion). Vaccines sales edged up 2% YoY to GBP 2.7 billion (USD 3.6 billion), while General Medicines grew 4% to GBP 2.5 billion (USD 3.3 billion).
Key Product Performance in Q3 ’25
- Shingrix (shingles vaccine) – sales up 13% to GBP 830 million (USD 1.1 billion), with a modest slowdown in China.
- Arexvy (RSV vaccine) – up 36% to GBP 251 million (USD 334 million), reflecting reduced demand in the U.S.
- Nucala (asthma drug) – 14% increase to GBP 499 million (USD 664 million).
- Benlysta (lupus therapy) – 17% rise to GBP 447 million (USD 595 million).
- Jemperli (endometrial‑cancer drug) – 79% jump to GBP 230 million (USD 306 million).
Guidance Revision
The robust performance prompted GSK to lift its full‑year outlook. Revenue growth is now projected at 6‑7% (up from 3‑5%), core operating profit growth at 9‑11% (up from 6‑8%), and core earnings per share (EPS) growth at 10‑12% (up from 6‑8%).-Fineline Info & Tech
